2,502 reports of this reaction
2.0% of all CARBAMAZEPINE reports
#11 most reported adverse reaction
CONVULSION is the #11 most commonly reported adverse reaction for CARBAMAZEPINE, manufactured by Novartis Pharmaceuticals Corporation. There are 2,502 FDA adverse event reports linking CARBAMAZEPINE to CONVULSION. This represents approximately 2.0% of all 124,512 adverse event reports for this drug.
Patients taking CARBAMAZEPINE who experience convulsion should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
CONVULSION is a less commonly reported adverse event for CARBAMAZEPINE, but still significant enough to appear in the safety profile.
In addition to convulsion, the following adverse reactions have been reported for CARBAMAZEPINE:
The following drugs have also been linked to convulsion in FDA adverse event reports:
CONVULSION has been reported as an adverse event in 2,502 FDA reports for CARBAMAZEPINE. This does not prove causation, but indicates an association observed in post-market surveillance data.
CONVULSION accounts for approximately 2.0% of all adverse event reports for CARBAMAZEPINE, making it a notable side effect.
If you experience convulsion while taking CARBAMAZEPINE, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.